Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3486 - Selective internal radiation therapy (SIRT) in metastatic colorectal cancer (mCRC): Safety, efficacy and survival outcomes from the South Australian registry


08 Oct 2016


Poster Display


Adeola Ayoola


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


A. Ayoola1, S. Vantandoust1, A. Roy2, T.J. Price3, M. Kitchener4, D. Roder5, S. Quinn6, G. Kichenadasse7, C. Piantadosi8, R. Padbury9, C. Karapetis2

Author affiliations

  • 1 Department Of Medical Oncology, Flinders Medical Center, 5042 - Bedford Park/AU
  • 2 Medical Oncology, Flinders Medical Centre and Flinders University, Adelaide/AU
  • 3 Haematology And Oncology, The Queen Elizabeth Hospital and University of Adelaide, 5011 - Adelaide/AU
  • 4 Department Of Nuclear Medicine, The Queen Elizabeth Hospital, 5011 - Adelaide/AU
  • 5 Population Health, University of South Australia, Adelaide/AU
  • 6 School Of Medicine, Flinders University, 5042 - Adelaide/AU
  • 7 Medical Oncology, Flinders Medical Centre and Flinders University, 5042 - Adelaide/AU
  • 8 Flinders Center For Innovation In Cancer, Flinders University, 5042 - Adelaide/AU
  • 9 Department Of Surgery, Flinders Medical Centre and Flinders University, Adelaide/AU


Abstract 3486


Colorectal cancer remains one of the commonly diagnosed cancers. The liver is the most common site of metastatic disease and the majority of patients eventually die from cancer progression in the liver. We report on the South Australian experience of the use of liver directed treatment with SIRT and we analyze the safety and efficacy of this intervention.


Data was obtained from the State-wide Metastatic Colorectal Cancer Registry which was established in 2006. Patients treated with SIRT were identified. The objectives were to determine time to progression in the liver, overall survival, response rate, acute toxicity and safety of SIRT. 55 patients (37 males; 18 Females) were treated with SIRT from 2006-2015. The median age was 67.5 years. 70% had ECOG score 


The median time to hepatic progression was 3.72 (95% CI. 2.26-4.83) months; the median survival was 10.6 (95% CI. 7.73-15.32) months. Patients with liver limited disease vs extra-hepatic disease showed no difference in median survival (14.2 vs 10.6months, p = 0.67). In other univariable analyses, there was no significant difference in survival according to age, ECOG, lines of chemotherapy, number of liver lesions or presence of extra-hepatic disease. The radiological response rate was 14.2%. There was no grade 3 or 4 acute toxicity. The most common short-term adverse effects were hepatic pain (18%), nausea, vomiting and back pain. Data regarding potential long term toxicity was not systemically collected.


In this population based analysis, SIRT was mostly administered in pre-treated patients and we observed activity with an acceptable short term safety profile.

Clinical trial identification

Not applicable

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings